HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story 6-month HIV PrEP makes coverage gains ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

Men who have sex with men (MSM) who are HIV-negative reported interest in an injectable pre-exposure prophylaxis (PrEP) that lasted longer than the daily pill, regardless of cost or coverage. This ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...